Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. More Details
+ 1 more risk
Excellent balance sheet and overvalued.
Share Price & News
How has Cann Global's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CGB is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: CGB's weekly volatility has decreased from 28% to 17% over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
1 Year Return
Return vs Industry: CGB underperformed the Australian Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: CGB underperformed the Australian Market which returned 37.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cann Global's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StWhat Can We Make Of Cann Global's (ASX:CGB) CEO Compensation?
7 months ago | Simply Wall StHow Much Does Cann Global's (ASX:CGB) CEO Make?
11 months ago | Simply Wall StDoes Cann Global Limited's (ASX:CGB) CEO Salary Compare Well With Others?
Is Cann Global undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CGB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CGB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CGB is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: CGB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CGB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CGB is good value based on its PB Ratio (2.1x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Cann Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cann Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cann Global performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CGB is currently unprofitable.
Growing Profit Margin: CGB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CGB is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare CGB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: CGB has a negative Return on Equity (-24.48%), as it is currently unprofitable.
How is Cann Global's financial position?
Financial Position Analysis
Short Term Liabilities: CGB's short term assets (A$13.5M) exceed its short term liabilities (A$2.0M).
Long Term Liabilities: CGB's short term assets (A$13.5M) exceed its long term liabilities (A$60.7K).
Debt to Equity History and Analysis
Debt Level: CGB's debt to equity ratio (0.5%) is considered satisfactory.
Reducing Debt: CGB's debt to equity ratio has increased from 0.07% to 0.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CGB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CGB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.3% each year
What is Cann Global current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CGB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CGB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CGB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CGB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CGB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sholom Feldman (44 yo)
Mr. Sholom Dovber Feldman serves as the Chief Executive Officer of Cann Global Limited (formerly Queensland Bauxite Limited) (Formerly, Australian Gold Investments Limited) since 2007 and serves as its Man...
CEO Compensation Analysis
Compensation vs Market: Sholom's total compensation ($USD242.54K) is about average for companies of similar size in the Australian market ($USD287.37K).
Compensation vs Earnings: Sholom's compensation has been consistent with company performance over the past year.
Experienced Management: CGB's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: CGB's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 71.1%.
Cann Global Limited's company bio, employee growth, exchange listings and data sources
- Name: Cann Global Limited
- Ticker: CGB
- Exchange: ASX
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$37.152m
- Shares outstanding: 5.72b
- Website: https://www.canngloballimited.com
- Cann Global Limited
- 133 Castlereagh Street
- Level 21
- New South Wales
Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Eva...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 08:31|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.